【摘要】：目的探討粉塵螨Ⅲ類(lèi)重組變應(yīng)原(rDer f 3)對(duì)過(guò)敏性哮喘小鼠的免疫治療效果。方法隨機(jī)將40只BALB/c小鼠均分為4組,哮喘組、免疫治療組、卵清蛋白(OVA)組和PBS組,分別在第0、第7和第14天哮喘組和免疫治療組每鼠經(jīng)腹腔注射100μl致敏液(含rDer f 3 10μg);卵清蛋白組每鼠經(jīng)腹腔注射100μl致敏液(含OVA 10μg);PBS組則以PBS代替致敏液。第21天起,哮喘組和免疫治療組小鼠用rDer f 3進(jìn)行滴鼻激發(fā)試驗(yàn),連續(xù)7 d,免疫治療組小鼠在第25~27天滴鼻激發(fā)前30 min,用100μg rDer f 3純化蛋白皮下注射進(jìn)行特異性免疫治療。PBS組和卵清蛋白組則分別用PBS和OVA進(jìn)行滴鼻激發(fā)和腹腔注射,最后1次滴鼻激發(fā)24 h后脫臼處死小鼠。收集各組小鼠支氣管肺泡灌洗液(BALF)進(jìn)行白細(xì)胞和嗜酸粒細(xì)胞計(jì)數(shù);對(duì)肺組織病理切片進(jìn)行HE染色,鏡下觀察肺組織炎癥細(xì)胞浸潤(rùn)情況。ELISA檢測(cè)BALF和脾細(xì)胞培養(yǎng)上清(SSCS)中白細(xì)胞介素-5(IL-5)和γ干擾素(IFN-γ)及血清中變應(yīng)原特異性IgE、IgG2a抗體水平。結(jié)果肺組織病理切片結(jié)果顯示,免疫治療組小鼠炎癥反應(yīng)明顯減輕。小鼠BALF中白細(xì)胞總數(shù)在免疫治療組、卵清蛋白組和哮喘組分別為(7.03±1.38)×108/ml、(22.11±3.70)×108/ml和(22.75±3.24)×108/ml,免疫治療組低于卵清蛋白組和哮喘組(P0.01),嗜酸粒細(xì)胞的變化趨勢(shì)與白細(xì)胞類(lèi)似。免疫治療組、卵清蛋白組和哮喘組BALF中IL-5的水平分別為(108.20±11.02)pg/ml、(182.04±13.94)pg/ml和(195.33±15.33)pg/ml,SSCS中IL-5的水平分別為(98.34±13.06)pg/ml、(208.26±10.63)pg/ml和(179.54±13.65)pg/ml,免疫治療組均明顯低于卵清蛋白組和哮喘組(P0.01)。而IFN-γ含量則高于卵清蛋白組和哮喘組(P0.01)。IgE水平免疫治療組、卵清蛋白組和哮喘組分別為(9.12±3.78)IU/ml、(26.87±4.30)IU/ml和(35.25±8.84)IU/ml,與卵清蛋白組和哮喘組相比,免疫治療組明顯降低(P0.01),而IgG2a水平(38.52±6.33)μg/ml則顯著升高(P0.01)。結(jié)論粉塵螨Ⅲ類(lèi)變應(yīng)原可逆轉(zhuǎn)哮喘小鼠的變態(tài)反應(yīng)性氣道及肺部炎癥。
[Abstract]:Objective to investigate the effect of recombinant allergen (rDer f 3 on allergic asthma mice. Methods 40 BALB/c mice were randomly divided into 4 groups: asthma group, immunotherapy group, ovalbumin (OVA) group and PBS group. On the 7th and 14th days, asthma group and immunotherapy group were injected intraperitoneally with 100 渭 l sensitization solution (including rDer f 3 10 渭 g);). In ovalbumin group, 100 渭 l sensitizing solution was injected intraperitoneally. In 10 渭 g); PBS group containing OVA, PBS was used instead of sensitizing solution. From the 21st day, mice in asthma group and immunotherapy group were given nasal drip challenge test with rDer f3 for 7 days. The mice in immunotherapy group were given nasal drip challenge 30 min, before nasal drip on day 2527. The specific immunotherapy was performed by subcutaneous injection of 100 渭 g rDer f 3 purified protein. In PBS group and ovalbumin group, PBS and OVA were used for nasal drip and intraperitoneal injection, respectively. The mice were killed after 24 hours of nasal drip. (BALF) in bronchoalveolar lavage fluid was collected to count leukocytes and eosinophils in each group. The pathological sections of lung were stained with HE. ELISA was used to detect the levels of interleukin-5 (IL-5) and interferon 緯 (IFN- 緯) in (SSCS) and serum anti-allergen specific IgE,IgG2a antibody. Results the pathological section of lung tissue showed that the inflammatory reaction in immunotherapy group was obviously alleviated. The total number of leukocytes in BALF in immunotherapy group, ovalbumin group and asthma group were (7.03 鹵1.38) 脳 108 / ml, (22.11 鹵3.70) 脳 108/ml and (22.75 鹵3.24) 脳 108 / ml, respectively. The immunotherapy group was lower than ovalbumin group and asthma group (P0.01). The levels of IL-5 in BALF of immunotherapy group, ovalbumin group and asthma group were (108.20 鹵11.02) pg/ml, (182.04 鹵13.94) pg/ml and (195.33 鹵15.33) pg/ml, respectively. The levels of IL-5 in SSCS (98.34 鹵13.06) pg/ml, (208.26 鹵10.63) pg/ml and (179.54 鹵13.65) pg/ml, immunotherapy group were significantly lower than those in ovalbumin group and asthma group (P0.01). The levels of IFN- 緯 in ovalbumin group and asthma group were higher than those in ovalbumin group and asthma group (P0.01). IgE level), and the IU/ml, levels in ovalbumin group and asthma group were (9.12 鹵3.78) IU/ml, respectively. Compared with ovalbumin group and asthma group, (26.87 鹵4.30) IU/ml and (35.25 鹵8.84) IU/ml, decreased significantly (P0.01), while IgG2a level (38.52 鹵6.33) 渭 g/ml increased significantly (P0.01). Conclusion Class 鈪，

本文編號(hào)：2348031